Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The details of trafficking and processing of APP to Aβ, the cytosolic intracellular Aβ domain (AICD) and small soluble proteins are shown, together with other amyloid-forming proteins such as tau and α-synuclein (α-syn).
|
30605056 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APP/PS1 mice also exhibited higher amyloid-β40 and amyloid-β42 in their cortex, accumulation of mitochondria APP in their cortex, and presented an altered oxidative state in their brain.
|
31016475 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In Alzheimer's disease, BACE1 protease initiates the amyloidogenic processing of amyloid precursor protein (APP) that eventually results in synthesis of β-amyloid (Aβ) peptide.
|
31701556 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, the therapeutic effects of topiramate were investigated in a transgenic mouse model of cerebral amyloidosis (APP/PS1 mice).
|
31248209 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The experimental results showed that VAC at sub-micromolar concentrations improved the viability of neural cells with or without increased β-amyloid (Aβ) burden; and in APP/PS1 transgenic mice, VAC treatment (0.1 mmol kg<sup>-1</sup> d<sup>-1</sup>) preserved cognitive function and attenuated neuron loss, but did not reduce brain Aβ plaques.
|
30136058 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To better study the consequences of reducing BACE metabolism, specifically of APP, we used an antibody, 2B3, that binds to APP at the BACE cleavage site, inhibiting Aβ production.
|
30572184 |
2019 |
Amyloidosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By contrast, in younger age groups, APP expression is not associated with amyloidosis, instead it acts solely as a neuroprotectant while facilitating cellular ferroportin-dependent iron efflux.
|
30823541 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in amyloid precursor protein (APP) cleavage and production of the APP fragment beta-amyloid (Aβ) along with hyperphosphorylated tau protein aggregation coalesce to cause reduction in synaptic strength, synaptic loss, and neurodegeneration.
|
31753135 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, spinosin reduced Aβ<sub>1-42</sub> production by impacting the procession of APP.
|
31791116 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treadmill exercise decreases β-amyloid burden in APP/PS1 transgenic mice involving regulation of the unfolded protein response.
|
30905823 |
2019 |
Amyloidosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that absence of TYROBP/DAP12 in a mouse model of AD-type cerebral Aβ amyloidosis (APP<sup>KM670/671NL</sup>/PSEN1<sup>Δexon9</sup>) recapitulates the expected network characteristics by normalizing the transcriptome of APP/PSEN1 mice and repressing the induction of genes involved in the switch from homeostatic microglia to disease-associated microglia (DAM), including Trem2, complement (C1qa, C1qb, C1qc, and Itgax), Clec7a and Cst7.
|
30283032 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Characterization of Epileptic Spiking Associated With Brain Amyloidosis in APP/PS1 Mice.
|
31781019 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beta-amyloid (Aβ) is a peptide that derives from the proteolytic cleavage of the amyloid precursor protein (APP) by several secretases.
|
30471405 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of justicidin A on Aβ production was blocked by endocytosis inhibitors, indicating that the decreased APP endocytosis by justicidin A is the underlying mechanism.
|
30332887 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APP plays a greater role in AD pathogenesis than its role as the precursor for Aβ peptides: both the abnormal cleavage of APP leading to Aβ peptide accumulation and the disruption of APP physiological functions contribute to AD pathogenesis.
|
31039414 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In human glioblastoma A172 cells and neuroblastoma SH-SY5Y cells, we delineated the Dl-NBP-mediated signaling pathways by which Dl-NBP-dependent upregulation of Nrf2 mediated the reciprocal regulation of reducing proinflammatory cytokine and inhibiting Aβ production in the glial and neuronal cells overexpressing APPswe.
|
29634349 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we have examined the effect of TBI on subsequent beta-amyloid (Aβ) deposition in APP/PS1 (APP<sub>SWE</sub>/PSEN1dE9) transgenic mice either before (3 months of age) or after the onset (6 months of age) of plaque pathology.
|
30623730 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP) is processed along the amyloidogenic pathway by the β-secretase, BACE1, generating β-amyloid (Aβ), or along the nonamyloidogenic pathway by α-secretase, precluding Aβ production.
|
30545942 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP) processing plays an important role in Aβ production, which initiates synaptic and neuronal damage.
|
30622228 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used transgenic mice expressing mutant human amyloid β-protein precursor and presenilin 1 (APP/PS1) to model cerebral amyloidosis.
|
30563837 |
2019 |
Amyloidosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TgF344-AD rat model of AD, bearing mutant human amyloid precursor protein (APPswe) and Presenilin 1 (PSEN1ΔE9) genes, has been described to manifest the full spectrum of AD pathology similar to human AD, i.e. progressive cerebral amyloidosis, tauopathy, neuronal loss and age-dependent cognitive decline.
|
30445024 |
2019 |
Amyloidosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined the occurrence of behavioral, cognitive and neuroimaging changes in APP<sup>NL-G-F</sup> knock-in mice that display Aβ42 amyloidosis in the absence of APP overexpression.
|
29158112 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that EPPS treatment profoundly reduced the accumulation of beta-amyloid precursor protein (β-APP) and Aβ over a widespread area detected in the pericontusional cortex, external capsule (EC), and hippocampal CA1 and CA3 at 3 days after TBI, accompanied by significant reduction in the TBI-induced diffuse axonal injury identified by increased immunoreactivity of SMI-32 (an indicator for axonal damage).
|
30639321 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that an antibiotic cocktail (ABX)-perturbed gut microbiome is associated with reduced amyloid-β (Aβ) plaque pathology and astrogliosis in the male amyloid precursor protein (<i>APP)<sub>SWE</sub></i> /presenilin 1 <i>(PS1)<sub>ΔE9</sub></i> transgenic model of Aβ amyloidosis.
|
31097468 |
2019 |
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic stress is a major risk factor for developing Alzheimer's disease (AD) and promotes the processing of amyloid precursor protein (APP) to β-amyloid (Aβ).
|
31231836 |
2019 |